This Viewpoint describes the FDA’s guidance on digital tools that seeks to balance technological innovation with assurances that medical mobile apps and other devices that fall within the agency’s regulatory purview are safe and effective.
No takes yet. Share an insight, caveat, or question.
Shuren et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: